Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Transbuccal delivery of doxepin: studies on permeation and histological investigation.

Gimeno A, Calpena AC, Sanz R, Mallandrich M, Peraire C, Clares B.

Int J Pharm. 2014 Dec 30;477(1-2):650-4. doi: 10.1016/j.ijpharm.2014.10.060. Epub 2014 Nov 1.

PMID:
25445535
2.

Population pharmacokinetic modelling of irosustat in postmenopausal women with oestrogen-receptor positive breast cancer incorporating non-linear red blood cell uptake.

Parra-Guillen ZP, Cendrós Carreras JM, Peraire C, Obach R, Prunynosa J, Chetaille E, Trocóniz IF.

Pharm Res. 2015 Apr;32(4):1493-504. doi: 10.1007/s11095-014-1555-4. Epub 2014 Oct 30.

PMID:
25355461
3.

A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.

Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A, Ali T, Schmid P.

Breast Cancer Res Treat. 2013 Jul;140(1):73-82. Epub 2013 Jun 25.

PMID:
23797179
4.

Skin permeation of cacalol, cacalone and 6-epi-cacalone sesquiterpenes from a nanoemulsion.

Garduño-Ramírez ML, Clares B, Domínguez-Villegas V, Peraire C, Ruiz MA, García ML, Calpena AC.

Nat Prod Commun. 2012 Jul;7(7):821-3.

PMID:
22908555
5.

Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.

Trocóniz IF, Cendrós JM, Soto E, Pruñonosa J, Perez-Mayoral A, Peraire C, Principe P, Delavault P, Cvitkovic F, Lesimple T, Obach R.

Cancer Chemother Pharmacol. 2012 Aug;70(2):239-50. doi: 10.1007/s00280-012-1906-y. Epub 2012 Jun 15.

PMID:
22699813
6.

Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.

Romero E, Vélez de Mendizabal N, Cendrós JM, Peraire C, Bascompta E, Obach R, Trocóniz IF.

J Pharmacol Exp Ther. 2012 Sep;342(3):788-98. doi: 10.1124/jpet.112.195560. Epub 2012 Jun 12.

PMID:
22691297
7.

In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.

Ventura V, Solà J, Peraire C, Brée F, Obach R.

Drug Metab Dispos. 2012 Jul;40(7):1268-78. doi: 10.1124/dmd.111.044271. Epub 2012 Mar 26.

PMID:
22451700
8.

Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.

Kim J, Peraire C, Solà J, Johanning KM, Dalton JT, Veverka KA.

Xenobiotica. 2011 Oct;41(10):851-62. doi: 10.3109/00498254.2011.590546. Epub 2011 Jul 5.

PMID:
21726172
9.

Pharmacodynamic modeling of the effects of lanreotide Autogel on growth hormone and insulin-like growth factor 1.

Garrido MJ, Cendrós JM, Ramis J, Peraire C, Obach R, Trocóniz IF.

J Clin Pharmacol. 2012 Apr;52(4):487-98. doi: 10.1177/0091270011399761. Epub 2011 May 6.

PMID:
21551318
10.

In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification.

Ventura V, Solà J, Celma C, Peraire C, Obach R.

Drug Metab Dispos. 2011 Jul;39(7):1235-46. doi: 10.1124/dmd.111.038315. Epub 2011 Apr 4.

PMID:
21464173
11.

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.

Soto E, Keizer RJ, Trocóniz IF, Huitema AD, Beijnen JH, Schellens JH, Wanders J, Cendrós JM, Obach R, Peraire C, Friberg LE, Karlsson MO.

Invest New Drugs. 2011 Oct;29(5):984-95. doi: 10.1007/s10637-010-9437-z. Epub 2010 May 7.

12.

Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.

Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, Lloberas N, Pou L, Peraire C, Grinyó JM.

Antimicrob Agents Chemother. 2009 Nov;53(11):4816-24. doi: 10.1128/AAC.00085-09. Epub 2009 Sep 8.

13.

Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.

Colom H, Farré R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J, Mangues MA.

Ther Drug Monit. 2009 Feb;31(1):76-85. doi: 10.1097/FTD.0b013e3181945624.

PMID:
19077931
14.

Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Trocóniz IF, Cendrós JM, Peraire C, Ramis J, Garrido MJ, Boscani PF, Obach R.

Clin Pharmacokinet. 2009;48(1):51-62. doi: 10.2165/0003088-200948010-00004.

15.

Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.

Tomlinson B, Thomas NG, Lan IW, Barbanoj M, Antonijoan RM, Drazna E, Ramis J, Obach R, Peraire C.

Clin Pharmacokinet. 2006;45(10):1003-11.

PMID:
16984213
16.

Biological stability and osteoconductivity in rabbit tibia of pulsed laser deposited hydroxylapatite coatings.

Peraire C, Arias JL, Bernal D, Pou J, León B, Arañó A, Roth W.

J Biomed Mater Res A. 2006 May;77(2):370-9.

PMID:
16425242
17.

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.

Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.

Cancer Chemother Pharmacol. 2006 Jun;57(6):727-35. Epub 2005 Oct 28.

PMID:
16261364
18.

Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.

Cendros JM, Peraire C, Trocóniz IF, Obach R.

Metabolism. 2005 Oct;54(10):1276-81.

PMID:
16154424
19.
20.

Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.

Antonijoan RM, Barbanoj MJ, Cordero JA, Peraire C, Obach R, Vallès J, Chérif-Cheikh R, Torres ML, Bismuth F, Montes M.

J Pharm Pharmacol. 2004 Apr;56(4):471-6.

PMID:
15099442
21.

Absolute bioavailability and absorption profile of cyanamide in man.

Colom H, Pruñonosa J, Peraire C, Domenech J, Azcona O, Torrent J, Obach R.

J Pharmacokinet Biopharm. 1999 Aug;27(4):421-36.

PMID:
10826131
22.

Simultaneous determination of paracetamol and chlorpheniramine in human plasma by liquid chromatography-tandem mass spectrometry.

Celma C, Allué JA, Pruñonosa J, Peraire C, Obach R.

J Chromatogr A. 2000 Feb 18;870(1-2):77-86.

PMID:
10722064
23.

Determination of N-acetylcysteine in human plasma by liquid chromatography coupled to tandem mass spectrometry.

Celma C, Allué JA, Pruñonosa J, Peraire C, Obach R.

J Chromatogr A. 2000 Feb 18;870(1-2):13-22.

PMID:
10722057
24.

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency.

Barbanoj M, Antonijoan R, Morte A, Grinyó JM, Solà R, Vallès J, Peraire C, Cordero JA, Muñoz A, Jané F, Obach R.

Clin Pharmacol Ther. 1999 Nov;66(5):485-91.

PMID:
10579475
25.

Influence of d-limonene on the transdermal penetration of felodipine.

Diez I, Peraire C, Obach R, Domenech J.

Eur J Drug Metab Pharmacokinet. 1998 Jan-Mar;23(1):7-12.

PMID:
9625266
26.

Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extraction.

Pruñonosa J, Solà J, Peraire C, Pla F, Lavergne O, Obach R.

J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):388-92.

PMID:
8704947
27.

Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction.

Pruñonosa J, Parera L, Peraire C, Pla F, Lavergne O, Obach R.

J Chromatogr B Biomed Appl. 1995 Jun 23;668(2):281-90.

PMID:
7581863
28.

Pharmacokinetic study of cicletanine in healthy volunteers.

Pruñonosa J, Peraire C, Torrent J, Obach R.

Int J Clin Pharmacol Ther Toxicol. 1992 Aug;30(8):265-70.

PMID:
1526688
29.

A comparative in vitro study of transdermal absorption of a series of calcium channel antagonists.

Diez I, Colom H, Moreno J, Obach R, Peraire C, Domenech J.

J Pharm Sci. 1991 Oct;80(10):931-4.

PMID:
1784001
30.

Pharmacokinetics and oral bioavailability of carbimide in man.

Obach R, Torrent J, Colom H, Pruñonosa J, Peraire C, Domenech J.

Biopharm Drug Dispos. 1991 Aug-Sep;12(6):425-34.

PMID:
1932606
31.

Reduction of oral bioavailability of paracetamol by tolmetin in rat.

Sabater J, Peraire C, Obach R, Moreno J, Domenech J.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:61-5.

PMID:
1820937
32.

Comparative study "in vitro" of transdermal absorption of a series of antiemetic drugs.

Blanes C, Colom H, Moreno J, Obach R, Peraire C, Domenech J.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:410-4.

PMID:
1820914
33.

Lack of correlation between pharmacokinetic and pharmacodynamic behaviour of cyanamide in man. A preliminary report.

Obach R, Pruñonosa J, Torrent J, Colom H, Peraire C, Izquierdo I, Domenech J.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:185-90.

PMID:
1820876
34.

Multiple dose pharmacokinetic study of cicletanine in healthy volunteers.

Peraire C, Torrent J, Pruñonosa J, Azcona O, Nomen M, Obach R.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:173-7.

PMID:
1820874
35.

Intestinal absorption kinetics of a series of aminopenicillins and azidocillin. A comparative study in the rat.

Margarit F, Moreno-Dalmau J, Obach R, Peraire C, Plá-Delfina JM.

Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:102-7.

PMID:
1820862
36.

Study of the release process of drugs: suppositories of paracetamol.

Lauroba J, Diez I, Rius M, Peraire C, Domenech J.

Int J Clin Pharmacol Ther Toxicol. 1990 Mar;28(3):118-22.

PMID:
2318548
37.

Pharmacokinetics of cyanamide in dog and rat.

Obach R, Colom H, Arso J, Peraire C, Pruñonosa J.

J Pharm Pharmacol. 1989 Sep;41(9):624-7.

PMID:
2573707

Supplemental Content

Loading ...
Support Center